Trials / Recruiting
RecruitingNCT06610344
BHB & CAR-T for Lymphomas
Preliminary Investigation of β-hydroxybutyrate Supplementation for Lymphoma Patients Receiving Anti-CD19 CAR T-cells
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 5 (estimated)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to assess the feasibility of β-hydroxybutyrate (BHB) supplementation in individuals who are receiving therapy for lymphoma with standard-of-care anti-CD19 CAR T-cells (CAR-T) to determine whether BHB supplementation is safe and tolerable in this patient population. Additionally, this study will determine whether BHB supplementation leads to changes the gut microbiome and peripheral blood mononuclear cells (PBMCs). BHB supplementation will be performed through oral administration of HVMN Ketone-IQ, a commercially available BHB supplement, with an active ingredient of R- 1,3-Butanediol, which is converted to BHB.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | R-1,3-Butanediol | R-1,3-Butanediol 35 mL |
Timeline
- Start date
- 2025-01-07
- Primary completion
- 2026-09-15
- Completion
- 2027-09-15
- First posted
- 2024-09-24
- Last updated
- 2026-02-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06610344. Inclusion in this directory is not an endorsement.